Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib

被引：31

作者：

Latagliata, Roberto ^{[1
]}

Breccia, Massimo ^{[1
]}

Castagnetti, Fausto ^{[2
]}

Stagno, Fabio ^{[3
]}

Luciano, Luigiana ^{[4
]}

Gozzini, Antonella ^{[5
]}

Ulisciani, Stefano ^{[6
]}

Cavazzini, Francesco ^{[7
]}

Annunziata, Mario ^{[8
]}

Sora, Federica ^{[9
]}

Rossi, Antonella Russo ^{[10
]}

Pregno, Patrizia ^{[11
]}

Montefusco, Enrico ^{[12
]}

Abruzzese, Elisabetta ^{[13
]}

Crisa, Elena ^{[14
]}

Musto, Pellegrino ^{[15
]}

Tiribelli, Mario ^{[16
]}

Binotto, Gianni ^{[17
]}

Occhini, Ubaldo ^{[18
]}

Feo, Costanzo ^{[19
]}

Vigneri, Paolo ^{[3
]}

Santini, Valeria ^{[5
]}

Fava, Carmen ^{[6
]}

Rosti, Giannantonio ^{[2
]}

Alimena, Giuliana ^{[1
]}

机构：

[1] Univ Roma La Sapienza, Dipartimento Biotecnol Cellulari & Ematol, I-00161 Rome, Italy

[2] Univ Bologna, Bologna, Italy

[3] Osped Ferrarotto, Catania, Italy

[4] Univ Naples Federico II, Naples, Italy

[5] Univ Florence, Firenza, Italy

[6] Polo Univ ASO San Luigi Gonzaga, Orbassano, Italy

[7] Univ Ferrara, I-44100 Ferrara, Italy

[8] Osped Cardarelli, Naples, Italy

[9] Univ Cattolica Sacro Cuore, Rome, Italy

[10] Univ Bari, Bari, Italy

[11] Osped San Giovanni Battista, Turin, Italy

[12] Osped St Andrea, Rome, Italy

[13] Osped St Eugenio, Rome, Italy

[14] Univ Turin, Div Ematol, Turin, Italy

[15] Ctr Riferimento Oncol Basilicata, IRCCS, Dipartimento Oncoematol, Vulture, Italy

[16] Univ Udine, I-33100 Udine, Italy

[17] Univ Padua, Padua, Italy

[18] Osped San Donato, Arezzo, Italy

[19] AO Rummo, DH Ematol, Benevento, Italy

来源：

LEUKEMIA RESEARCH | 2011年 / 35卷 / 09期

关键词：

Chronic Myeloid Leukaemia; Dasatinib; Elderly; Safety; DURABLE CYTOGENETIC RESPONSES; BCR-ABL; CHRONIC-PHASE; FOLLOW-UP; RESISTANCE; CML; RECOMMENDATIONS; INTOLERANCE; INHIBITORS; BMS-354825;

D O I：

10.1016/j.leukres.2011.05.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To highlight dasatinib role in the elderly, 125 unselected patients with CP-CML aged >60 years resistant/intolerant to imatinib were retrospectively evaluated. Grade 3-4 haematological and extra-haematological toxicities were reported in 39 (31.2%) and 34 (27.2%) patients; grade 3-4 haematological toxicity was higher in patients with 140 mg starting dose (50.0% vs 19.6%, p = 0.001). Grade 3-4 pleuro-pericardial effusions occurred in 10 patients (8.0%). Dose reductions were more common in patients with 140 mg (88.4% vs 26.7%, p < 0.001). Of 122 evaluable patients, 72 (59.1%) had cytogenetic response [12 (9.8%) partial, 60 (49.3%) complete]. Overall, 38/60 patients in complete CyR also achieved a molecular response. Cumulative OS at 24 and 48 months were 93.1% (95% CI 88.4-97.8) and 84.2% (95% CI 74.6-93.7). Dasatinib, at the recommended dose of 100 mg/day, is effective and safe also in unselected elderly subjects. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：1164 / 1169

页数：6

共 19 条

[1] Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Baccarani, Michele
Saglio, Giuseppe
Goldman, John
Hochhaus, Andreas
Simonsson, Bengt
Appelbaum, Frederick
Apperley, Jane
Cervantes, Francisco
Cortes, Jorge
Deininger, Michael
Gratwohl, Alois
Guilhot, Frangois
Horowitz, Mary
Hughes, Timothy
Kantarjian, Hagop
Larson, Richard
Niederwieser, Dielger
Silver, Richard
Hehlmann, Rudiger
[J]. BLOOD, 2006, 108 (06) : 1809 - 1820
[2] Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
Branford, S
Rudzki, Z
Walsh, S
Parkinson, I
Grigg, A
Szer, J
Taylor, K
Herrmann, R
Seymour, JF
Arthur, C
Joske, D
Lynch, K
Hughes, T
[J]. BLOOD, 2003, 102 (01) : 276 - 283
[3] Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
Branford, Susan
Fletcher, Linda
Cross, Nicholas C. P.
Mueller, Martin C.
Hochhaus, Andreas
Kim, Dong-Wook
Radich, Jerald P.
Saglio, Giuseppe
Pane, Fabrizio
Kamel-Reid, Suzanne
Wang, Y. Lynn
Press, Richard D.
Lynch, Kevin
Rudzki, Zbigniew
Goldman, John M.
Hughes, Timothy
[J]. BLOOD, 2008, 112 (08) : 3330 - 3338
[4] BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria
Branford, Susan
Seymour, John F.
Grigg, Andrew
Arthur, Chris
Rudzki, Zbigniew
Lynch, Kevin
Hughes, Timothy
[J]. CLINICAL CANCER RESEARCH, 2007, 13 (23) : 7080 - 7085
[5] Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia
Cortes, J
Talpaz, M
O'Brien, S
Giles, F
Rios, MB
Shan, JQ
Faderl, S
Garcia-Manero, G
Ferrajoli, A
Wierda, W
Kantarjian, H
[J]. CANCER, 2003, 98 (06) : 1105 - 1113
[6] Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Druker, Brian J.
Guilhot, Francois
O'Brien, Stephen G.
Gathmann, Insa
Kantarjian, Hagop
Gattermann, Norbert
Deininger, Michael W. N.
Silver, Richard T.
Goldman, John M.
Stone, Richard M.
Cervantes, Francisco
Hochhaus, Andreas
Powell, Bayard L.
Gabrilove, Janice L.
Rousselot, Philippe
Reiffers, Josy
Cornelissen, Jan J.
Hughes, Timothy
Agis, Hermine
Fischer, Thomas
Verhoef, Gregor
Shepherd, John
Saglio, Giuseppe
Gratwohl, Alois
Nielsen, Johan L.
Radich, Jerald P.
Simonsson, Bengt
Taylor, Kerry
Baccarani, Michele
So, Charlene
Letvak, Laurie
Larson, Richard A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) : 2408 - 2417
[7] Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
Hochhaus, A.
Baccarani, M.
Deininger, M.
Apperley, J. F.
Lipton, J. H.
Goldberg, S. L.
Corm, S.
Shah, N. P.
Cervantes, F.
Silver, R. T.
Niederwieser, D.
Stone, R. M.
Dombret, H.
Larson, R. A.
Roy, L.
Hughes, T.
Mueller, M. C.
Ezzeddine, R.
Countouriotis, A. M.
Kantarjian, H. M.
[J]. LEUKEMIA, 2008, 22 (06) : 1200 - 1206
[8] Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment
Hochhaus, Andreas
Druker, Brian
Sawyers, Charles
Guilhot, Francois
Schiffer, Charles A.
Cortes, Jorge
Niederwieser, Dietger W.
Gambacorti, Carlo
Stone, Richard M.
Goldman, John
Fischer, Thomas
O'Brien, Stephen G.
Reiffers, Jose J.
Mone, Manisha
Krahnke, Tillmann
Talpaz, Moshe
Kantarjian, Hagop M.
[J]. BLOOD, 2008, 111 (03) : 1039 - 1043
[9] Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
Hochhaus, Andreas
Kantarjian, Hagop M.
Baccarani, Michele
Lipton, Jeffrey H.
Apperley, Jane F.
Druker, Brian J.
Facon, Thierry
Goldberg, Stuart L.
Cervantes, Francisco
Niederwieser, Dietger
Silver, Richard T.
Stone, Richard M.
Hughes, Timothy P.
Muller, Martin C.
Ezzeddine, Rana
Countouriotis, Athena M.
Shah, Neil P.
[J]. BLOOD, 2007, 109 (06) : 2303 - 2309
[10] Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Hughes, Timothy
Deininger, Michael
Hochhaus, Andreas
Branford, Susan
Radich, Jerald
Kaecla, Jaspal
Baccarani, Michele
Cortes, Jorge
Cross, Nicholas C. P.
Druker, Brian J.
Gabert, Jean
Grimwade, David
Hehlmann, Ruediger
Kamel-Reid, Suzanne
Lipton, Jeffrey H.
Longtine, Janina
Martinelli, Giovanni
Saglio, Giuseppe
Soverini, Simona
Stock, Wendy
Goldman, John M.
[J]. BLOOD, 2006, 108 (01) : 28 - 37

← 1 2 →